**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 59586

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Epidemiological and clinical characteristics of 65 hospitalized patients with COVID-19 in Liaoning, China**

Zhang W *et al.* Clinical features of COVID-19 cases in Liaoning

Wei Zhang, Yuan Ban, Yun-Hai Wu, Jin-Yang Liu, Xing-Hai Li, Hao Wu, Huan Li, Rui Chen, Xiao-Xu Yu, Rui Zheng

**Wei Zhang, Hao Wu, Huan Li, Rui Chen, Xiao-Xu Yu, Rui Zheng,** Department of Pulmonary and Critical Care Medicine, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China

**Yuan Ban, Yun-Hai Wu,** Department of Critical Care Medicine, The Sixth People's Hospital of Shenyang, Shenyang 110006, Liaoning Province, China

**Jin-Yang Liu, Xing-Hai Li,** Department of Infectious Diseases, The Sixth People's Hospital of Shenyang, Shenyang 110006, Liaoning Province, China

**Author contributions:** Zhang W contributed to study design, data analysis, and manuscript drafting and revision; Ban Y, Wu YH, Liu JY, and Li XH contributed to this work with regard to data collection and manuscript revision; Wu H, Li H, Chen R, and Yu XX contributed to data analysis and manuscript revision; Zheng R had a contribution in conceptual work, study design, and revising of the manuscript; all co-authors have given the final approval of the version to be published.

**Supported by** 345 Talent Program of Shengjing Hospital; and Scientific Research Projects Related to Prevention and Control of Coronavirus Disease 2019 (COVID-19) of China Medical University, No. 1210120010.

**Corresponding author: Rui Zheng, MD, PhD, Chief Physician, Deputy Director, Doctor, Professor,** Department of Pulmonary and Critical Care Medicine, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang 110004, Liaoning Province, China. zhengr@sj-hospital.org

**Received:** September 22, 2020

**Revised:** January 15, 2021

**Accepted:** February 11, 2021

**Published online:** April 6, 2021

**Abstract**

BACKGROUND

Coronavirus disease 2019 (COVID-19) has spread rapidly to multiple countries through its infectious agent severe acute respiratory syndrome coronavirus 2. The severity, atypical clinical presentation, and lack of specific anti-viral treatments have posed a challenge for the diagnosis and treatment of COVID-19.Understanding the epidemiological and clinical characteristics of COVID-19 cases in different geographical areasis essential to improve the prognosis of COVID-19 patients and slow the spread of the disease.

AIM

To investigate the epidemiological and clinical characteristics and main therapeutic strategy for confirmed COVID-19 patients hospitalized in Liaoning Province, China.

METHODS

Adult patients (*n* = 65) with confirmed COVID-19 were enrolled in this retrospective study from January 20 to February 29, 2020 in Liaoning Province, China. Pharyngeal swabs and sputum specimens were collected from the patients for the detection of severe acute respiratory syndrome coronavirus 2 nucleic acid. Patient demographic information and clinical data were collected from the medical records. Based on the severity of COVID-19, the patients were divided into nonsevere and severe groups. All patients were followed until March 20, 2020.

RESULTS

Themean age of 65 COVID-19 patients was 45.5 ± 14.4 years, 56.9% were men, and 24.6% were severe cases. During the 14 d before symptom onset, 25 (38.5%) patients lived or stayed in Wuhan, whereas 8 (12.3%) had no clear history of exposure. Twenty-nine (44.6%) patients had at least one comorbidity; hypertension and diabetes were the most common comorbidities. Compared with nonsevere patients, severe patients had significantly lower lymphocyte counts [median value 1.3 × 109/L (interquartile range 0.9-1.95) *vs* 0.82 × 109/L (0.44-1.08), *P* < 0.001], elevated levels of lactate dehydrogenase [450 U/L (386-476) *vs* 707 U/L (592-980), *P* < 0.001] and C-reactive protein [6.1 mg/L (1.5-7.2) *vs* 52 mg/L (12.7-100.8), *P* < 0.001], and a prolonged median duration of viral shedding [19.5 d (16-21) *vs* 23.5 d (19.6-30.3), *P* = 0.001].The overall median viral shedding time was 19.5 d, and the longest was 53 d.Severe patients were more frequently treated with lopinavir/ritonavir, antibiotics, glucocorticoid therapy, immunoglobulin, thymosin, and oxygen support.All patients were discharged following treatment in quarantine.

CONCLUSION

Our findings may facilitate the identification of severe cases and inform clinical treatment and quarantine decisions regarding COVID-19.

**Key Words:** Coronavirus disease; COVID-19; Epidemiology; Liaoning; SARS-CoV-2; Viral pneumonia

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

Zhang W, Ban Y, Wu YH, Liu JY, Li XH, Wu H, Li H, Chen R, Yu XX, Zheng R. Epidemiological and clinical characteristics of 65 hospitalized patients with COVID-19 in Liaoning, China. *World J Clin Cases* 2021; 9(10): 2205-2217 URL: https://www.wjgnet.com/2307-8960/full/v9/i10/2205.htm DOI: https://dx.doi.org/10.12998/wjcc.v9.i10.2205

**Core Tip:** This study describes the clinical and laboratory characteristics of 65 adult coronavirus disease 2019 (COVID-19) patients who were diagnosed and treated in Liaoning Province. The prevalence of afebrile patients was significantly higher in nonsevere COVID-19 patients than in severe patients, whereas severe COVID-19 patients were more likely to have lymphopenia and elevated levels of lactate dehydrogenase and C-reactive protein. The longer median duration of viral shedding in severe patients should be noted to improve transmission control measures.

**INTRODUCTION**

The ongoing spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously 2019-nCoV), the virus that causes coronavirus disease 2019 (COVID-19), continues worldwide[1] and poses a constant threat to global public health[2]. On March 11, 2020, the World Health Organization (WHO) declared COVID-19 a pandemic, and more than 88 million infections and almost 1.9 million deaths from more than 200 countries, areas, or territories as of January 10, 2021[1]. The most-affected regions as of January 10, 2021 are the Americas and Europe, which are not only responsible for 77% of cumulative cases and 80% of cumulative deaths globally but also for the majority of new cases and deaths[1]. According to the Centers for Disease Control and Prevention, as of January 13, 2021, over 22 million COVID-19 cases have been confirmed in the United States, and 379255 patients have died due to the disease[3]. Many countries have imposed restrictions on the movement[4-6] of people to limit the spread of SARS-CoV-2 and reduce the burden on health systems, but these measures have brought a heavy economic cost and global economic decline[6].

In the early stage of the coronavirus outbreak in China, the government employed two strategies-containment and suppression-in an attempt to prevent and control COVID-19 spread. Thereafter, the number ofnew cases of COVID-19 in China declined, and internationally imported cases or second-generation cases from importations accounted for the majority of new COVID-19 cases[7]. In December 2020, there were 104 new confirmed cases of COVID-19 in China, representing an increase of 76.3% over November. During the New Year's Day and Spring Festival there was an increase in the number of overseas returnees; high mobility of domestic personnel; more gathering activities, especially indoor activities; and a rise in imported cold-chain food and cargo logistics. All of these factors are believed to have contributed to an increased transmission risk of SARS-CoV-2[8]. Therefore, the epidemic situation in China remains severe and complicated. As of January 13, 2021, SARS-CoV-2 has caused 4635 deaths out of 87844 confirmed cases in mainland China[9], of which 68149 (77.6%) cases occurred in Hubei Province[10], and 396 (0.045‰) occurred in Liaoning Province[11]. Several recent studies have indicated that COVID-19 case frequency and/or mortality vary according to population characteristics, socioeconomic status, climate, and social distancing interventions[12-15]. Previous studies in China have mainly documented the epidemiological and clinical characteristics of COVID-19 cases in Hubei Province[16-19]; however, descriptions of confirmed cases in Liaoning Province have remained limited to date[20].

This study aimed to analyze the epidemiological, clinical, and laboratory characteristics as well as the main therapeutic strategy for hospitalized COVID-19 patients in Liaoning Province, China.

**MATERIALS AND METHODS**

***Study design and subjects***

This retrospective observational study included 65 COVID-19 patients (≥ 18 years old) on whom the principle investigator of this study participated in the clinical guidance, as a member of the Liaoning Province COVID-19 medical treatment expert team from January 20 to February 29, 2020 in Liaoning Province, China. Throat swabs and sputum samples from suspected SARS-CoV-2 infected patients were obtained to detect viral nucleic acid using real-time reverse transcription-polymerase chain reaction. The patients were divided into two groups: Nonsevere group and severe group based on the level of COVID-19 severity.

This case series was approved by the Medical Ethics Committee of Shengjing Hospital of China Medical University (reference number 2020PS065K).

***Data collection and definitions***

Demographics and clinical data of patients, including age, sex, medical history, exposure history, comorbidities, signs and symptoms, laboratory findings, chest computed tomographic (CT) findings, and treatment measures, were retrospectively collected. Patients were discharged when deemed clinically recovered, including afebrile for at least 3 d, resolution of symptoms, radiologic improvement, and two negative results of consecutive nucleic acid tests taken at least 24 h apart. Clinical outcomes were followed until March 20, 2020.

The date of disease onset was defined as the day when the first symptoms were noticed. Fever was considered as an increase in body temperature above 37.2 °C. The level of COVID-19 severity was defined according to the New Coronavirus Pneumonia Diagnosis and Treatment Protocol (Trial Version 8) released by China’s National Health Commission[21]. Adult COVID-19 cases meeting at least one of the following criteria were considered to have severe COVID-19: (1) Shortness of breath with a respiratory rate > 30 breaths/min; (2) Oxygen saturation level using a pulse oximeter ≤ 93% at rest; (3) Oxygenation index (partial pressure of artery oxygen/fraction of inspired oxygen, PaO2/FiO2) ≤ 300 mmHg; or (4) Progressively worsening clinical symptoms with pulmonary imaging showing significant progression of lesions within 24-48 h > 50%.

***Statistical analysis***

Categorical variables are reported as frequencies and percentages, and continuous variables are described using the mean and standard deviation, or median and interquartile range (IQR) according to the normality of distribution. Missing values of the variables were filled with median or mean imputation. Differences between groups were compared using the Student’s *t*-test or the Mann-Whitney *U* test for quantitative variables according to their distribution, and the *χ2* test or Fisher exact test when appropriate for categorical variables. Statistical significance was represented by a *P* value < 0.05. All statistical analyses were performed with Statistic Package for Social Science (IBM Statistic Package for Social Science Statistics 21.0).

**RESULTS**

***Epidemiological and clinical characteristics***

This study involved 65 SARS-CoV-2 infected patients with pneumonia, all of whom were confirmed and treated in Liaoning Province. Among them, 25 (38.5%) patients lived or stayed in Wuhan within 14 d after confirmation of COVID-19, 5 (7.7%) lived or stayed in Hubei Province except Wuhan, 27 (41.5%) who were residents of Liaoning Province had an exposure to confirmed cases, and 8 (12.3%) who were residents of Liaoning Province had no clear exposure history. There were no significant differences between the nonsevere and severe groups in the percentages of potential exposure to the source of infection within 14 d after confirmation of COVID-19 (Figure 1). The 65 patients were neither hospital workers nor did they have a direct exposure history to the Huanan Seafood Wholesale Market or wildlife animals in Wuhan.

Of the 65 patients, 49 (75.4%) and 16 (24.6%) were classified into the nonsevere and severe groups, respectively (Table 1). The mean age was 45.5 ± 14.4 years, and 37 (56.9%) were men. The mean time from illness onset to first hospital admission was 4.7 ± 3.5 d. Twenty-nine (44.6%) patients had at least one underlying comorbidity; hypertension (15.4%), diabetes (13.8%), cardiovascular disease (6.2%), and chronic liver disease (6.2%) were the most frequent comorbidities. The most commonly experienced symptoms were fever (70.8%) and dry cough (60%), followed by expectoration (29.2%), fatigue (24.6%), dyspnea (17.2%), and pharyngalgia (12.3%). Other less common symptoms included myalgia, runny or stuffy nose, headache, diarrhea, nausea or vomiting, chest pain, and hemoptysis. In addition, eight nonsevere patients showed no clinical symptoms since the onset of illness. As expected, the prevalence of dyspnea was higher in severe patients than in nonsevere patients (40% *vs* 10.2%, *P* = 0.022). Furthermore, compared with severe patients, afebrile was more frequent in nonsevere patients (38.8% *vs* 0%, *P* = 0.008).

***Radiological and laboratory findings***

Based on chest CT scans, 53 (81.5%) patients showed bilateral lung involvement, and a small amount of pleural effusion was found in 3 (4.6%) patients (Table 2). No lung cavitation was observed. Additionally, pure ground-glass opacity (GGO) occurred in 24 (36.9%) patients, and GGO and consolidation were observed in 41 (63.1%) patients. The chest CT images of nonsevere patients were more likely to show pure GGO compared to severe patients (46.9% *vs* 6.3%, *P* = 0.003). In contrast, GGO and consolidation were more frequently observed in severe patients than in nonsevere patients (53.1% *vs* 93.8%, *P* = 0.003). A peripheral distribution of pulmonary infiltrates was demonstrated in all patients; however, there were no statistical differences between the two groups in the proportion of peripheral and central pulmonary lesions.

Overall, blood cell counts in the majority of patients were within normal limits, excluding the lymphocyte count that was notably lower in severe cases than in nonsevere cases [1.3 × 109/L (IQR: 0.9-1.95) *vs* 0.82 × 109/L (IQR: 0.44-1.08), *P* < 0.001]. Moreover, severe patients showed higher levels of D-dimer, blood urea nitrogen, creatine kinase, and creatine kinase-MB, despite the median values of these laboratory tests for the two groups being within their corresponding normal range. Markedly elevated levels of C-reactive protein (CRP) [6.1 mg/L (IQR: 1.5-7.2) *vs* 52 (IQR: 12.7-100.8), *P* < 0.001] and lactate dehydrogenase (LDH) [450 U/L (IQR: 386-476) *vs* 707 (IQR: 592-980), *P* < 0.001] were observed in severe patients than in nonsevere patients.

The duration of viral shedding from illness onset ranged from 4 to 53 d, and the median duration of viral shedding was 19.5 d (IQR: 17-24). Notably, severe patients showed a longer median duration of viral shedding from illness onset than nonsevere patients [19.5 d (IQR: 16-21) *vs* 23.5 (IQR: 19.6-30.3), *P* = 0.001]. The severity of illness scores for hospitalized patients with COVID-19 is shown in Table 3.

***Outcomes and treatments***

As of March 20, 2020, all patients had been discharged after undergoing treatment in isolation. Except for four nonsevere cases, the remaining 61 (93.8%) patients were administered antiviral treatment (Table 4). Overall, 36 (55.4%) patients were given empirical antibiotic treatment, including moxifloxacin (46.1%), levofloxacin (4.6%), cefoperazone sodium and sulbactam sodium (4.6%), carbopenems (9.2%), linezolid (4.6%), and caspofungin (1.5%). Expectedly, severe patients were more likely to receive lopinavir/ritonavir (LPV/r), antibiotics, glucocorticoid therapy, immunoglobulin, thymosin, and oxygen support than nonsevere patients. The prone position was intermittently used to improve oxygenation in six patients with severe hypoxemia, four of whom received oxygen *via* high-flow nasal cannula and the other two received oxygen *via* regular nasal cannulas. Consequently, oxygenation was significantly improved in five patients after being placed in the prone position. Only one of the six patients, whose hypoxemia did not improve rapidly, received subsequent noninvasive ventilation, invasive mechanical ventilation, extracorporeal membrane oxygenation, and pulmonary rehabilitation. Finally, this 41-year-old male patient recovered following antiviral, glucocorticoid, and antibiotic therapies.

**DISCUSSION**

Owing to the high infectivity and high pathogenicity of SARS-CoV-2, the rising number of COVID-19 cases has caused global public health concerns. Here, we report the results of a comparative analysis of 49 nonsevere and 16 severe cases with pneumonia diagnosed and treated as COVID-19 in Liaoning Province. Nearly 12.3% of the patients did neither live in nor visit Hubei Province; they also had no exposure history of direct contact with confirmed COVID-19 cases. Thus, we speculate that in these COVID-19 cases, transmission was likely linked to asymptomatic COVID-19 patients[22,23] mainly through inhalation of respiratory droplets or contact with contaminated surfaces[24]. In contrast to our data, Guan *et al*[25] reported in their study of patients from 552 hospitals in China, the percentage reporting no direct contact with confirmed COVID-19 cases reached a higher rate, at nearly 25.9%. In another study of 94 COVID-19 patients in China, the proportion of presymptomatic transmission was reported to be approximately 44%[26]. These findings suggested that as potential sources of SARS-CoV-2 infection, the identification and management of asymptomatic cases or presymptomatic COVID-19 patients should be strengthened.

The median age of COVID-19 patients was previously reported to range from 49 to 57 years in Wuhan[16-19,27]. The mean age of patients in our study was slightly lower (45.5 years), but similar to recent data from Beijing (median age 47.5 years)[28] and another selected cohort of patients throughout China (median age 47 years)[25]. Despite people of any age being susceptible to SARS-CoV-2[29], older age has been associated with higher mortality[18,30] and more frequent severe COVID-19 cases than younger age[16,17], as observed in the present study.

In agreement with recent findings[17,18], our data showed hypertension and diabetes as the most frequent underlying diseases in infected people. Nevertheless, our study failed to find a significantly larger proportion of underlying diseases in severe patients than in nonsevere patients, as reported in recent studies[16,17]. The main reason for this discrepancy may be the younger mean age and/or a smaller sample size in our study. The most common clinical symptoms of COVID-19 in the present study included fever, cough, fatigue, dyspnea, and pharyngalgia, consistent with other recent reports[16]. Interestingly, our results showed that 17 (34.7%) patients with nonsevere COVID-19 had no febrile response and the occurrence of fever and dyspnea was remarkably higher than that in severe patients (0%). This suggests that COVID-19 patients with stable vital signs, who lack fever or dyspnea, may be relatively mild cases, excluding those with impaired immune function.

Regarding radiological findings, in this study bilateral involvement (81.5%), peripheral distribution (100%), and GGO (100%) were the most common chest CT manifestations of COVID-19, and pleural effusions (4.6%) were rare. Notably, our results showed that critically ill patients had a higher incidence of GGO with consolidation (93.8%) than nonsevere patients (53.1%). Similarly, in other studies, it has been observed that as the illness progressed, GGO in chest CT images of COVID-19 patients increased, enlarged, and consolidated[31]. These findings may help clinicians recognize the time-course and severity of COVID-19.

As expected, compared to nonsevere COVID-19 patients, we observed notable increased levels of D-dimer, creatine kinase-MB, LDH, and blood urea nitrogen in severe patients, suggesting that coagulation derangements, myocardial injury, and decreased renal function were more common in severe COVID-19 cases[32]. Recent studies showed the association of lymphopenia with the severity and poor prognosis of COVID-19[18,33]. It has been demonstrated that SARS-CoV-2 infection leads to the functional exhaustion of cytotoxic lymphocytes and the breakdown of antiviral immunity in the early stage of infection[34]. We did not find significantly elevated serum procalcitonin levels in our patients, which may indicate that increased concentrations of other inflammatory markers, such as CRP and LDH, are due to a SARS-CoV-2 infection rather than a bacterial infection. CRP has been extensively used as a marker of inflammation in clinical practice. In the host innate immune response, CRP is involved in recognition of viral infection[35], activation of complement, and promoting the inflammatory response in severe influenza infection[36]. Previous studies found that high levels of CRP and LDH in COVID-19 patients were correlated with more severe COVID-19 illness[18,37]. In the present study, 43.1% of COVID-19 patients had lymphopenia, and severe patients with COVID-19 had significantly lower absolute lymphocyte counts and abnormally higher levels of CRP and LDH than nonsevere patients. These results are similar to previously reported data[16,17,38]. This suggests that the maladjusted immune response and excessive activation of the inflammatory response are more likely to occur in critically ill patients with COVID-19, and thus contribute to pulmonary tissue damage, functional impairment, and deterioration of severe COVID-19 patients.

Previous reports of COVID-19 cases found that the viral load from the respiratory tract declined after the first week of symptom onset[39,40]. The results of the present study show that the median viral shedding time for COVID-19 from throat swabs or sputum samples was 19.5 d, which was close to the finding of 20.0 d reported by Zhou *et al*[18], but longer than 12.0 d reported by Qian *et al*[41]. We found that the longest viral shedding time for COVID-19 persisted for 53 d, in contrast to 37 d and 34 d in other reports[18,41]. The 53-d viral shedding time was found in the nonsevere COVID-19 case of a 66-year-old man with a history of diabetes, hypertension, and intracerebral hemorrhage; he was treated with arbidol. However, the reason for the prolonged shedding time in this case remains unclear, and host factors may have contributed. Zhou *et al*[18] recently reported that SARS-CoV-2 ribonucleic acid from respiratory tract samples was present until death in non-survivors. Similarly, ours results showed that the median duration of viral shedding in the severe COVID-19 group was 4 d longer than that of the nonsevere group. Understanding the duration and pattern of viral shedding in individuals infected with SARS-CoV-2 could help reduce exposure to and transmission of SARS-CoV-2 and improve infection control.

To date, no antiviral drug has been fully proven effective for COVID-19, and some potential vaccine candidates against COVID-19 have already reached phase 3 clinical trials[42]. Encouragingly, several COVID-19 vaccines, including Pfizer-BioNTech COVID-19 vaccine and Sinopharm vaccine, have been approved for conditional or emergency use in some countries, and these are expected to prevent SARS-CoV-2 infection and reduce the severity of the illness.

A recent *in vitro* study demonstrated that remdesivir and chloroquine were highly effective against SARS-CoV-2 infection[43]. Grein *et al*[44] observed clinical improvement in 68% of 53 COVID-19 patients treated with compassionate-use remdesivir. In addition, remdesivir was demonstrated to significantly shorten the timeto recovery compared to a placebo[45,46]. Despite the proven efficacy, in a trial with 1062 hospitalized patients with COVID-19[45], grade 3 or 4 adverse events with remdesivir therapy were reported in 51.3% of patients in the remdesivir group, while serious adverse events observed in 24.6% of patients. The WHO suggests against remdesivir except treating patients hospitalised with COVID-19 regardless of disease severity[47]. A retrospective cohort study reported that arbidol combined with LPV/r delayed the progression of lung injury and reduced viral load in COVID-19 patients[48], whereas a recent randomized controlled clinical trial in severe COVID-19 cases did not show any obvious benefit of LPV/r in clinical improvement, mortality, or throat viral ribonucleic acid detectability[49]. In the present study, according to Chinese clinical guidance for COVID-19 pneumonia diagnosis and treatment[21], antiviral drugs were empirically used in most patients, especially LPV/r in severe patients. As mentioned above, the patients in the present study did not show significantly high procalcitonin levels; thus, antibiotics were considered as compassionate use in 55.4% of the patients, including the application of linezolid and caspofungin in severe patients.

The evidence for corticosteroid therapy for COVID-19 is controversial and inconclusive, and systemic corticosteroids are recommended for the treatment of severe and critical COVID-19 patients according to the WHO living guidance[47]. Thus, corticosteroids were prescribed depending on disease severity and clinical experience in this study. Of 16 severe COVID-19 patients in the present study, 81.3% received LPV/r, 62.5% received corticosteroids, 50% received arbidol, and 43.8% received thymosin. These drugs may have been helpful in clinical improvement of these COVID-19 patients. In our study, in addition to medication, a 41-year-old male patient with severe COVID-19 received mechanical ventilation and extracorporeal membrane oxygenation in the early phase of acute respiratory distress syndrome, and he subsequently underwent an early pulmonary rehabilitation program after weaning, including prone position, respiratory training, physical exercises, psychological intervention, and sleep promotion. Early identification and mechanical ventilation of hypoxemia, prone position ventilation, and early pulmonary rehabilitation may contribute to improved oxygenation and survival among COVID-19 patients with acute respiratory distress syndrome[20,50].

Our study has several limitations. First, this observational study was subject to the limitations of a retrospective cohort design. Second, this study was limited by a relatively small sample size. Third, the estimated duration of viral shedding was limited by the frequency of respiratory specimen collection. Furthermore, the present study lacks information on COVID-19 patients who did not recover and survive.

**CONCLUSION**

In summary, our study findings and therapeutic regimens may provide useful information for the identification and treatment of severe cases, and inform quarantine practices for COVID-19 patients.

**ARTICLE HIGHLIGHTS**

***Research background***

Coronavirus disease 2019 (COVID-19) has spread rapidly to multiple countries, and the illness severity, the atypical clinical presentation, and lack of specific anti-viral treatment have posed a challenge for the diagnosis and treatment of COVID-19.

***Research motivation***

Understanding the epidemiological and clinical characteristics of COVID-19 cases in different geographical areas are essential to improve the prognosis of COVID-19 patients.

***Research objectives***

This study aimed to investigate the epidemiological and clinical characteristics and main therapeutic strategy for confirmed COVID-19 patients hospitalized in Liaoning Province, China.

***Research methods***

A total of 65 adult patients with confirmed COVID-19 were enrolled in this retrospective study from January 20 to February 29, 2020 in Liaoning Province, China. Based on the severity of COVID-19, the patients were divided into nonsevere and severe groups.

***Research results***

Compared with nonsevere patients (75.4%), severe patients (24.6%) had significantly lower lymphocyte counts, elevated levels of lactate dehydrogenase and C-reactive protein, and a longer median duration of viral shedding. The overall median viral shedding time was 19.5 d, and the longest was 53 d. Severe patients were more frequently treated with lopinavir/ritonavir, antibiotics, glucocorticoid therapy, immunoglobulin, thymosin, and oxygen support.

***Research conclusions***

Our findings may facilitate the identification of severe cases and inform clinical treatment and quarantine decisions regarding COVID-19 patients.

***Research perspectives***

The identification of severe cases with COVID-19 may help prevent poor outcomes, while the estimated duration of viral shedding may help inform quarantine decisions and prevent acute respiratory syndrome coronavirus 2 spread.

**ACKNOWLEDGEMENTS**

The authors thank Dr. Li-Qiang Zheng for his helpful advice on statistical analysis.

**REFERENCES**

1 **World Health Organization.** COVID-19 Weekly Epidemiological Update. [cited 12 January 2021]. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update---12-january-2021

2 **Fauci AS**, Lane HC, Redfield RR. Covid-19 - Navigating the Uncharted. *N Engl J Med* 2020; **382**: 1268-1269 [PMID: 32109011 DOI: 10.1056/NEJMe2002387]

3 **Centers for Disease Control and Prevention.** CDC COVID Data Tracker. [cited 14 January 2021]. Available from: https://covid.cdc.gov/covid-data-tracker/?eType=EmailBlastContent&eId=898fa3f2-6696-41d2-aa8d-d16239fbf0cc#cases\_casesper100klast7days

4 **Salje H**, Tran Kiem C, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, Andronico A, Hozé N, Richet J, Dubost CL, Le Strat Y, Lessler J, Levy-Bruhl D, Fontanet A, Opatowski L, Boelle PY, Cauchemez S. Estimating the burden of SARS-CoV-2 in France. *Science* 2020; **369**: 208-211 [PMID: 32404476 DOI: 10.1126/science.abc3517]

5 **Kraemer MUG**, Yang CH, Gutierrez B, Wu CH, Klein B, Pigott DM; Open COVID-19 Data Working Group, du Plessis L, Faria NR, Li R, Hanage WP, Brownstein JS, Layan M, Vespignani A, Tian H, Dye C, Pybus OG, Scarpino SV. The effect of human mobility and control measures on the COVID-19 epidemic in China. *Science* 2020; **368**: 493-497 [PMID: 32213647 DOI: 10.1126/science.abb4218]

6 **Han E**, Tan MMJ, Turk E, Sridhar D, Leung GM, Shibuya K, Asgari N, Oh J, García-Basteiro AL, Hanefeld J, Cook AR, Hsu LY, Teo YY, Heymann D, Clark H, McKee M, Legido-Quigley H. Lessons learnt from easing COVID-19 restrictions: an analysis of countries and regions in Asia Pacific and Europe. *Lancet* 2020; **396**: 1525-1534 [PMID: 32979936 DOI: 10.1016/S0140-6736(20)32007-9]

7 **Li Z**, Chen Q, Feng L, Rodewald L, Xia Y, Yu H, Zhang R, An Z, Yin W, Chen W, Qin Y, Peng Z, Zhang T, Ni D, Cui J, Wang Q, Yang X, Zhang M, Ren X, Wu D, Sun X, Li Y, Zhou L, Qi X, Song T, Gao GF, Feng Z; China CDC COVID-19 Emergency Response Strategy Team. Active case finding with case management: the key to tackling the COVID-19 pandemic. *Lancet* 2020; **396**: 63-70 [PMID: 32505220 DOI: 10.1016/S0140-6736(20)31278-2]

8 **National health commission of the People’s Republic of China.** Transcript of the press conference of the Joint Prevention and Control Mechanism of the State Council on December 30, 2020. [cited 30 December 2020]. Available from: http://www.nhc.gov.cn/xcs/fkdt/202012/4b72af6ad0ca4973a3880f322dd6b4c2.shtml

9 **National health commission of the People’s Republic of China.** Updates on the epidemic situation of COVID-19 in China on January 13, 2021. [cited 14 January 2021]. Available from: http://www.nhc.gov.cn/xcs/yqtb/202101/1cd117e46f2640a29d00d5e9323ca2e5.shtml

10 **Health commission of Hubei province.** Updates on the epidemic situation of COVID-19 in Hubei province at 24:00 on January 13, 2021. [cited 14 January 2021]. Available from: http://wjw.hubei.gov.cn/bmdt/dtyw/202101/t20210114\_3241501.shtml

11 **Health commission of Liaoning province.** Updates on the epidemic situation of COVID-19 in Liaoning province at 24:00 on January 13, 2021. [cited 14 January 2021]. Available from: http://wsjk.ln.gov.cn/wst\_wsjskx/202012/t20201230\_4062371.html

12 **Sobral MFF**, Duarte GB, da Penha Sobral AIG, Marinho MLM, de Souza Melo A. Association between climate variables and global transmission oF SARS-CoV-2. *Sci Total Environ* 2020; **729**: 138997 [PMID: 32353724 DOI: 10.1016/j.scitotenv.2020.138997]

13 **Matrajt L**, Leung T. Evaluating the Effectiveness of Social Distancing Interventions to Delay or Flatten the Epidemic Curve of Coronavirus Disease. *Emerg Infect Dis* 2020; **26**: 1740-1748 [PMID: 32343222 DOI: 10.3201/eid2608.201093]

14 **Wadhera RK**, Wadhera P, Gaba P, Figueroa JF, Joynt Maddox KE, Yeh RW, Shen C. Variation in COVID-19 Hospitalizations and Deaths Across New York City Boroughs. *JAMA* 2020; **323**: 2192-2195 [PMID: 32347898 DOI: 10.1001/jama.2020.7197]

15 **Loomba RS**, Aggarwal G, Aggarwal S, Flores S, Villarreal EG, Farias JS, Lavie CJ. Disparities in case frequency and mortality of coronavirus disease 2019 (COVID-19) among various states in the United States. *Ann Med* 2021; **53**: 151-159 [PMID: 33138653 DOI: 10.1080/07853890.2020.1840620]

16 **Wang D**, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020; **323**: 1061-1069 [PMID: 32031570 DOI: 10.1001/jama.2020.1585]

17 **Zhang JJ**, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy* 2020; **75**: 1730-1741 [PMID: 32077115 DOI: 10.1111/all.14238]

18 **Zhou F**, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**: 1054-1062 [PMID: 32171076 DOI: 10.1016/S0140-6736(20)30566-3]

19 **Huang C**, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497-506 [PMID: 31986264 DOI: 10.1016/S0140-6736(20)30183-5]

20 **Zhu C**, Wu Y, Liu H, Ban Y, Ma X, Zhang Z. Early pulmonary rehabilitation for SARS-CoV-2 pneumonia: Experience from an intensive care unit outside of the Hubei province in China. *Heart Lung* 2020; **49**: 449-450 [PMID: 32312554 DOI: 10.1016/j.hrtlng.2020.04.007]

21 **National Health Commission of the People’s Republic of China.** New Coronavirus Pneumonia Diagnosis and Treatment Protocol (Trial Version 8). [cited 19 December 2020]. Available from: http://www.gov.cn/zhengce/zhengceku/2020-08/19/content\_5535757.htm

22 **Rothe C**, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, Zimmer T, Thiel V, Janke C, Guggemos W, Seilmaier M, Drosten C, Vollmar P, Zwirglmaier K, Zange S, Wölfel R, Hoelscher M. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. *N Engl J Med* 2020; **382**: 970-971 [PMID: 32003551 DOI: 10.1056/NEJMc2001468]

23 **Li R**, Pei S, Chen B, Song Y, Zhang T, Yang W, Shaman J. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). *Science* 2020; **368**: 489-493 [PMID: 32179701 DOI: 10.1126/science.abb3221]

24 **Lancet COVID-19 Commissioners, Task Force Chairs, and Commission Secretariat.** Lancet COVID-19 Commission Statement on the occasion of the 75th session of the UN General Assembly. *Lancet* 2020; **396**: 1102-1124 [PMID: 32941825 DOI: 10.1016/S0140-6736(20)31927-9]

25 **Guan WJ**, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020; **382**: 1708-1720 [PMID: 32109013 DOI: 10.1056/NEJMoa2002032]

26 **He X**, Lau EHY, Wu P, Deng X, Wang J, Hao X, Lau YC, Wong JY, Guan Y, Tan X, Mo X, Chen Y, Liao B, Chen W, Hu F, Zhang Q, Zhong M, Wu Y, Zhao L, Zhang F, Cowling BJ, Li F, Leung GM. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med* 2020; **26**: 672-675 [PMID: 32296168 DOI: 10.1038/s41591-020-0869-5]

27 **Chen N**, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020; **395**: 507-513 [PMID: 32007143 DOI: 10.1016/S0140-6736(20)30211-7]

28 **Tian S**, Hu N, Lou J, Chen K, Kang X, Xiang Z, Chen H, Wang D, Liu N, Liu D, Chen G, Zhang Y, Li D, Li J, Lian H, Niu S, Zhang L, Zhang J. Characteristics of COVID-19 infection in Beijing. *J Infect* 2020; **80**: 401-406 [PMID: 32112886 DOI: 10.1016/j.jinf.2020.02.018]

29 **Singhal T**. A Review of Coronavirus Disease-2019 (COVID-19). *Indian J Pediatr* 2020; **87**: 281-286 [PMID: 32166607 DOI: 10.1007/s12098-020-03263-6]

30 **O'Driscoll M**, Ribeiro Dos Santos G, Wang L, Cummings DAT, Azman AS, Paireau J, Fontanet A, Cauchemez S, Salje H. Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature* 2020 [PMID: 33137809 DOI: 10.1038/s41586-020-2918-0]

31 **Pan Y**, Guan H, Zhou S, Wang Y, Li Q, Zhu T, Hu Q, Xia L. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. *Eur Radiol* 2020; **30**: 3306-3309 [PMID: 32055945 DOI: 10.1007/s00330-020-06731-x]

32 **Tjendra Y**, Al Mana AF, Espejo AP, Akgun Y, Millan NC, Gomez-Fernandez C, Cray C. Predicting Disease Severity and Outcome in COVID-19 Patients: A Review of Multiple Biomarkers. *Arch Pathol Lab Med* 2020; **144**: 1465-1474 [PMID: 32818235 DOI: 10.5858/arpa.2020-0471-SA]

33 **Tan L**, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, Wang Q, Miao H. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. *Signal Transduct Target Ther* 2020; **5**: 33 [PMID: 32296069 DOI: 10.1038/s41392-020-0148-4]

34 **Zheng M**, Gao Y, Wang G, Song G, Liu S, Sun D, Xu Y, Tian Z. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. *Cell Mol Immunol* 2020; **17**: 533-535 [PMID: 32203188 DOI: 10.1038/s41423-020-0402-2]

35 **Li G**, Fan Y, Lai Y, Han T, Li Z, Zhou P, Pan P, Wang W, Hu D, Liu X, Zhang Q, Wu J. Coronavirus infections and immune responses. *J Med Virol* 2020; **92**: 424-432 [PMID: 31981224 DOI: 10.1002/jmv.25685]

36 **Gao R**, Wang L, Bai T, Zhang Y, Bo H, Shu Y. C-Reactive Protein Mediating Immunopathological Lesions: A Potential Treatment Option for Severe Influenza A Diseases. *EBioMedicine* 2017; **22**: 133-142 [PMID: 28734805 DOI: 10.1016/j.ebiom.2017.07.010]

37 **Liu Y**, Yang Y, Zhang C, Huang F, Wang F, Yuan J, Wang Z, Li J, Li J, Feng C, Zhang Z, Wang L, Peng L, Chen L, Qin Y, Zhao D, Tan S, Yin L, Xu J, Zhou C, Jiang C, Liu L. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Sci China Life Sci* 2020; **63**: 364-374 [PMID: 32048163 DOI: 10.1007/s11427-020-1643-8]

38 **Leisman DE**, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, Hirayama AV, Mastroiani F, Turtle CJ, Harhay MO, Legrand M, Deutschman CS. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. *Lancet Respir Med* 2020; **8**: 1233-1244 [PMID: 33075298 DOI: 10.1016/S2213-2600(20)30404-5]

39 **Kim ES**, Chin BS, Kang CK, Kim NJ, Kang YM, Choi JP, Oh DH, Kim JH, Koh B, Kim SE, Yun NR, Lee JH, Kim JY, Kim Y, Bang JH, Song KH, Kim HB, Chung KH, Oh MD; Korea National Committee for Clinical Management of COVID-19. Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19. *J Korean Med Sci* 2020; **35**: e142 [PMID: 32242348 DOI: 10.3346/jkms.2020.35.e142]

40 **Wölfel R**, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, Niemeyer D, Jones TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brünink S, Schneider J, Ehmann R, Zwirglmaier K, Drosten C, Wendtner C. Virological assessment of hospitalized patients with COVID-2019. *Nature* 2020; **581**: 465-469 [PMID: 32235945 DOI: 10.1038/s41586-020-2196-x]

41 **Qian GQ**, Chen XQ, Lv DF, Ma AHY, Wang LP, Yang NB, Chen XM. Duration of SARS-CoV-2 viral shedding during COVID-19 infection. *Infect Dis (Lond)* 2020; **52**: 511-512 [PMID: 32275181 DOI: 10.1080/23744235.2020.1748705]

42 **Singh JA**, Upshur REG. The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials. *Lancet Infect Dis* 2020 [PMID: 33306980 DOI: 10.1016/S1473-3099(20)30923-3]

43 **Wang M**, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res* 2020; **30**: 269-271 [PMID: 32020029 DOI: 10.1038/s41422-020-0282-0]

44 **Grein J**, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D'Arminio Monforte A, Ismail S, Kato H, Lapadula G, L'Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T. Compassionate Use of Remdesivir for Patients with Severe Covid-19. *N Engl J Med* 2020; **382**: 2327-2336 [PMID: 32275812 DOI: 10.1056/NEJMoa2007016]

45 **Beigel JH**, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. *N Engl J Med* 2020; **383**: 1813-1826 [PMID: 32445440 DOI: 10.1056/NEJMoa2007764]

46 **Beigel JH**, Tomashek KM, Dodd LE. Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply. *N Engl J Med* 2020; **383**: 994 [PMID: 32649078 DOI: 10.1056/NEJMc2022236]

47 **Siemieniuk R**, Rochwerg B, Agoritsas T, Lamontagne F, Leo YS, Macdonald H, Agarwal A, Zeng L, Lytvyn L, Appiah JA, Amin W, Arabi Y, Blumberg L, Burhan E, Bausch FJ, Calfee CS, Cao B, Cecconi M, Chanda D, Cooke G, Du B, Dunning J, Geduld H, Gee P, Hashimi M, Hui DS, Kabra S, Kanda S, Kawano-Dourado L, Kim YJ, Kissoon N, Kwizera A, Laake JH, Machado FR, Mahaka I, Manai H, Mino G, Nsutedu E, Pshenichnaya N, Qadir N, Sabzwari S, Sarin R, Sharland M, Shen Y, Sri Ranganathan S, Souza J, Ugarte S, Venkatapuram S, Quoc Dat V, Vuyiseka D, Stegemann M, Wijewickrama A, Maguire B, Zeraatkar D, Bartoszko J, Ge L, Brignardello-Petersen R, Owen A, Guyatt G, Diaz J, Jacobs M, Vandvik PO. A living WHO guideline on drugs for covid-19. *BMJ* 2020; **370**: m3379 [PMID: 32887691 DOI: 10.1136/bmj.m3379]

48 **Deng L**, Li C, Zeng Q, Liu X, Li X, Zhang H, Hong Z, Xia J. Arbidol combined with LPV/r *vs* LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. *J Infect* 2020; **81**: e1-e5 [PMID: 32171872 DOI: 10.1016/j.jinf.2020.03.002]

49 **Cao B**, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. *N Engl J Med* 2020; **382**: 1787-1799 [PMID: 32187464 DOI: 10.1056/NEJMoa2001282]

50 **Bein T**, Grasso S, Moerer O, Quintel M, Guerin C, Deja M, Brondani A, Mehta S. The standard of care of patients with ARDS: ventilatory settings and rescue therapies for refractory hypoxemia. *Intensive Care Med* 2016; **42**: 699-711 [PMID: 27040102 DOI: 10.1007/s00134-016-4325-4]

**Footnotes**

**Institutional review board statement:** This study was approved by the Medical Ethics Committee from Shengjing Hospital of China Medical University (reference number 2020PS065K).

**Informed consent statement:** Patients were not required to give informed consent to the study.

**Conflict-of-interest statement:** We have no financial relationships to disclose.

**Data sharing statement:** The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** September 22, 2020

**First decision:** December 13, 2020

**Article in press:** February 11, 2021

**Specialty type:** Respiratory system

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Ampollini L, Jurman G, Saha S **S-Editor:** Zhang L **L-Editor:** Wang TQ **P-Editor:** Wang LL

**Figure Legends**

****

**Figure 1** **There were no significant differences between nonsevere and severe groups in the percentages of potential exposure to the source of infection within 14 d after confirmation of coronavirus disease 2019.**

**Table 1 Demographics and clinical characteristics of hospitalized patients with coronavirus disease 2019, *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristic** | **Total (*n* = 65)** | **Nonsevere (*n* = 49)** | **Severe (*n* = 16)** | ***P* value** |
| Age, yr | 45.5 ± 14.4 | 43.6 ± 14.2 | 51.2 ± 14.1 | 0.067 |
| Male sex | 37 (56.9) | 26 (53.1) | 11 (68.8) | 0.271 |
| Current and former smokers | 7 (10.8) | 3 (6.1) | 4 (25) | 0.099 |
| Comorbidities | 29 (44.6) | 20 (40.8) | 9 (56.3) | 0.281 |
| Diabetes mellitus | 9 (13.8) | 8 (16.3) | 1 (6.3) | 0.551 |
| Hypertension | 10 (15.4) | 9 (18.4) | 1 (6.3) | 0.443 |
| Cardiovascular disease | 4 (6.2) | 3 (6.1) | 1 (6.3) | 1 |
| Cerebrovascular disease | 1 (1.5) | 1 (2) | 0 (0) | 1 |
| Chronic bronchitis | 2 (3.1) | 1 (2) | 1 (6.3) | 0.435 |
| Chronic liver disease | 4 (6.2) | 4 (8.2) | 0 (0) | 0.565 |
| Signs and symptoms |  |  |  |  |
| Fever | 46 (70.8) | 30 (61.2) | 16 (100) | 0.008 |
| Highest temperature, °C | 37.9 ± 0.9 | 37.7 ± 0.9 | 38.5 ± 0.6 | < 0.001 |
| < 37.3 | 17 (26.2) | 17 (34.7) | 0 | NA |
| 37.3-38.5 | 30 (46.2) | 21 (42.9) | 9 (56.3) | NA |
| > 38.5 | 18 9 (7.7%) | 11 (22.4) | 7 (43.8) | NA |
| Dry cough | 39 (60) | 27 (55.1) | 12 (75) | 0.158 |
| Expectoration | 19 (29.2) | 14 (28.6) | 5 (31.3) | 1 |
| Dyspnea | 11 (17.2) | 5 (10.2) | 6 (40) | 0.022 |
| Fatigue | 16 (24.6) | 12 (24.5) | 4 (25) | 1 |
| Myalgia | 4 (6.2) | 2 (4.1) | 2 (12.5) | 0.252 |
| Pharyngalgia | 8 (12.3) | 6 (12.2) | 2 (12.5) | 1 |
| Stuffy and runny nose | 3 (4.6) | 1 (2) | 2 (12.5) | 0.147 |
| Hemoptysis | 2 (3.1) | 1 (2) | 1 (6.3) | 0.435 |
| Chest pain | 2 (3.1) | 1 (2) | 1 (6.3) | 0.435 |
| Headache | 3 (4.6) | 2 (4.1) | 1 (6.3) | 1 |
| Nausea | 3 (4.6) | 2 (4.1) | 1 (6.3) | 1 |
| Vomiting | 2 (3.1) | 2 (4.1) | 0 (0) | 1 |
| Diarrhea | 3 (4.6) | 2 (4.1) | 1 (6.3) | 1 |
| Days from illness onset to first hospital admission | 4.7 ± 3.5 | 4.4 ± 3.4 | 5.6 ± 3.9 | 0.218 |
| Heart rate, bpm1  | 82.6 ± 9 | 82.8 ± 9 | 82.1 ± 9.2 | 0.81 |
| Respiratory rate, bpm2 | 19 (18-20) | 18 (18-20) | 20 (18.3-20) | 0.084 |
| Mean arterial pressure, mm Hg  | 98.2 ± 12 | 98 ± 12.9 | 98.8 ± 9.1 | 0.819 |

1Beats per minute.

2Breaths per minute. NA: Not applicable.

**Table 2 Radiological and laboratory findings of hospitalized patients with coronavirus disease 2019**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Normal range** | **Total (*n* = 65)** | **Nonsevere (*n* = 49)** | **Severe (*n* = 16)** | ***P* value** |
| Chest CT findings, *n* (%) |  |  |  |  |  |
| Bilateral distribution | NA | 53 (81.5) | 37 (75.5) | 16 (100) | 0.069 |
| Pure ground-glass opacity | NA | 24 (36.9) | 23 (46.9) | 1 (6.3) | 0.003 |
| Ground-glass opacity and Consolidation | NA | 41 (63.1) | 26 (53.1) | 15 (93.8) | 0.003 |
| Peripheral distribution | NA | 65 (100) | 49 (100) | 16 (100) | NA |
| Peripheral and central distribution | NA | 26 (40) | 17 (34.7) | 9 (56.3) | 0.126 |
| Laboratory findings |  |  |  |  |  |
| White blood cell count, × 109/L | 3.5-9.5 | 5 (3.47-6.75) | 5 (3.47-6.8) | 5.01 (3.59-5.51) | 0.976 |
| Neutrophil count, × 109/L | 1.8-6.3 | 3.71 ± 2.58 | 3.26 ± 1.59 | 5.1 ± 4.2 | 0.104 |
| Lymphocyte count, × 109/L | 1.1-3.2 | 1.15 (0.83-1.78) | 1.3 (0.9-1.95) | 0.82 (0.44-1.08) | < 0.001 |
| < 1.0, *n* (%) | NA | 26 (40) | 15 (30.6) | 11 (68.8) | 0.007 |
| Monocyte count, × 109/L | 0.1-0.6 | 0.41 (0.3-0.41) | 0.4 (0.35-0.47) | 0.4 (0.3-0.4) | 0.253 |
| Platelet count, × 109/L | 125-350 | 200 ± 72 | 204 ± 79 | 188 ± 47 | 0.445 |
| Prothrombin time, s | 11-14  | 11.58 (10.5-12) | 11.5 (10.5-11.6) | 11.5 (10.4-12.2) | 0.788 |
| D-dimer, mg/L | 0-0.55 | 0.27 (0.18-0.44) | 0.27 (0.16-0.27) | 0.51 (0.27-0.81) | < 0.001 |
| Albumin, g/L | 35-50 | 35.6 ± 5.5 | 36.2 ± 5.2 | 33.6 ± 6.1 | 0.099 |
| Alanine aminotransferase, U/L | 0-40 | 29 (19.5-48.5) | 29 (17-40) | 41.5 (21.8-69.3) | 0.068 |
| Aspartate aminotransferase, U/L | 0-40 | 25 (20-31) | 25 (17-29) | 27.5 (22.3-43.5) | 0.105 |
| Total bilirubin, mmol/L | 3-22 | 18.5 ± 6.6 | 17.7 ± 6.1 | 21.1 ± 7.7 | 0.08 |
| Creatinine, μmol/L | 58-110 | 56.8 ± 13.8 | 56.6 ± 14.4 | 57.4 ± 12.2 | 0.843 |
| Blood urea nitrogen, mmol/L | 2.5-6.1 | 3.7 ± 1.1 | 3.6 ± 0.9 | 4.2 ± 1.3 | 0.046 |
| Creatine kinase, U/L | 55-170 | 50 (35-79) | 50 (32.5-62.5) | 74 (48.3-130) | 0.03 |
| Creatine kinase-MB, U/L | 0-16 | 2 (1-6.5) | 2 (1-4) | 5.5 (2-12.1) | 0.015 |
| Lactate dehydrogenase, U/L | 313-618 | 461 (407-614) | 450 (386-479) | 707 (592-980) | < 0.001 |
| > 618, *n* (%) | NA | 16 (24.6) | 4 (8.2) | 12 (75) | < 0.001 |
| Potassium, mmol/L | 3.5-5.1 | 4.1 ± 0.5 | 4.3 ± 0.5 | 3.8 ± 0.5 | 0.001 |
| Sodium, mmol/L | 137-145 | 134 ± 3.5 | 135 ± 3.1 | 132 ± 3.8 | 0.002 |
| C-reactive protein, mg/L | 0-8 | 6.2 (2.9-28.7) | 6.1 (1.5-7.2) | 52 (12.7-100.8) | < 0.001 |
| > 8, *n* (%) | NA | 21 (32.3) | 9 (18.4) | 12 (75) | < 0.001 |
| Procalcitonin, ng/mL | 0-0.25 | 0.04 (0.04-0.05) | 0.04 (0.04-0.05) | 0.043 (0.04-0.08) | 0.084 |
| Duration of viral shedding after COVID-19 onset | NA | 19.5 (17-24) | 19.5 (16-21) | 23.5 (19.6-30.3) | 0.001 |

CT: Computed tomography; COVID-19: Coronavirus disease 2019; NA: Not applicable.

**Table 3 Severity of Illness Scores of hospitalized patients with coronavirus disease 2019**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Total (*n* = 65)** | **Nonsevere (*n* = 49)** | **Severe (*n* = 16)** | ***P* value** |
| APACHE II | 4.8 ± 3.6 | 3.9 ± 2.9 | 7.4 ± 4.4 | 0.009 |
| SOFA | 1 (0-2) | 0 (0-1) | 3 (2-4) | < 0.001 |
| PSI | 49.5 ± 21.7 | 43.2 ± 18.5 | 68.7 ± 19.7 | < 0.001 |
| MuLBSTA | 5 (5-8) | 5 (4.5-7) | 9 (5-11) | < 0.001 |

APACHEII: Acute physiology and chronic health evaluation II; SOFA: Sequential organ failure assessment; PSI: Peumonia severity index.

**Table 4 Treatments and outcomes of hospitalized patients with coronavirus disease 2019, *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Total (*n* = 65)** | **Nonsevere (*n* = 49)** | **Severe (*n* = 16)** | ***P* value** |
| Antiviral therapy |  |  |  |  |
| Oseltamivir | 12 (18.5) | 8 (16.3) | 4 (25) | 0.685 |
| Arbidol | 40 (61.5) | 32 (65.3) | 8 (50) | 0.275 |
| Ribavirin | 3 (4.6) | 3 (6.1) | 0 | 0.569 |
| Lopinavir/Ritonavir | 35 (53.8) | 22 (44.9) | 13 (81.3) | 0.011 |
| Interferon | 21 (32.3) | 16 (32.7) | 5 (31.3) | 0.917 |
| Chloroquine | 1 (1.5) | 0 | 1 (6.3) | 0.246 |
| Antibiotic therapy | 36 (55.4) | 21 (42.9) | 15 (93.8) | < 0.001 |
| Antifungal therapy | 1 (1.5) | 0 | 1 (6.3) | 0.246 |
| Glucocorticoid therapy | 12 (18.5) | 2 (4.1) | 10 (62.5) | < 0.001 |
| Immunoglobulin | 3 (4.6) | 0 | 3 (18.8) | 0.013 |
| Thymosin | 11 (16.9) | 4 (8.2) | 7 (43.8) | 0.004 |
| Traditional Chinese medicine | 51 (78.5) | 38 (77.6) | 13 (81.3) | 1 |
| Oxygen support | 20 (30.8) | 4 (8.2) | 16 (100) | < 0.001 |
| Nasal cannulas | 20 (30.8) | 4 (8.2) | 16 (100) | < 0.001 |
| HFNC | 6 (9.2) | 0 | 6 (37.5) | < 0.001 |
| NIV | 1 (1.5) | 0 | 1 (6.3) | 0.246 |
| IMV | 1 (1.5) | 0 | 1 (6.3) | 0.246 |
| ECMO | 1 (1.5) | 0 | 1 (6.3) | 0.246 |
| Prone position  | 6 (9.2) | 0 | 6 (37.5) | < 0.001 |

COVID-19: Coronavirus disease 2019; HFNC: High-flow nasal cannula; NIV: Noninvasive ventilation; IMV: Invasive mechanical ventilation; ECMO: Extracorporeal membrane oxygenation.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**